A novel germline P53 splicing mutation in a pediatric patient with a second malignant neoplasm

Carolyn A. Felix, Eric A. Strauss, Domenico D'Amico, Maria Tsokos, Stefan Winter, Tetsuya Mitsudomi, Marion M. Nau, Deborah L. Brown, Ann M. Leahy, Marc E. Horowitz, David G. Poplack, Dan Costin, John D. Minna

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

A novel germline p53 splicing mutation was identified in a pediatric patient with two metachronous primary cancers that are constituent tumors of the Li-Fraumeni syndrome. Genomic DNA from the second tumor showed the same mutation and loss of heterozygosity at the p53 locus. The mutant mRNA and protein were present in the tumor tissue. In contrast, in the normal tissues bearing the germline mutation in the heterozygous state, predominantly normal mRNA was expressed and the mutant p53 protein was not detectable. The functional silence and relative lack of mutant p53 mRNA expression in the normal tissues of this patient may be caused by decreased stability or decreased production. If this proves a more general pattern of expression of mutant p53 in individuals with germline mutations, these findings may explain the paucity of tumors in individuals affected with the Li-Fraumeni syndrome.

Original languageEnglish (US)
Pages (from-to)1203-1210
Number of pages8
JournalOncogene
Volume8
Issue number5
StatePublished - May 1993

Fingerprint

Second Primary Neoplasms
Pediatrics
Mutation
Li-Fraumeni Syndrome
Germ-Line Mutation
Mutant Proteins
Neoplasms
Messenger RNA
Loss of Heterozygosity
DNA

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Biology

Cite this

Felix, C. A., Strauss, E. A., D'Amico, D., Tsokos, M., Winter, S., Mitsudomi, T., ... Minna, J. D. (1993). A novel germline P53 splicing mutation in a pediatric patient with a second malignant neoplasm. Oncogene, 8(5), 1203-1210.

A novel germline P53 splicing mutation in a pediatric patient with a second malignant neoplasm. / Felix, Carolyn A.; Strauss, Eric A.; D'Amico, Domenico; Tsokos, Maria; Winter, Stefan; Mitsudomi, Tetsuya; Nau, Marion M.; Brown, Deborah L.; Leahy, Ann M.; Horowitz, Marc E.; Poplack, David G.; Costin, Dan; Minna, John D.

In: Oncogene, Vol. 8, No. 5, 05.1993, p. 1203-1210.

Research output: Contribution to journalArticle

Felix, CA, Strauss, EA, D'Amico, D, Tsokos, M, Winter, S, Mitsudomi, T, Nau, MM, Brown, DL, Leahy, AM, Horowitz, ME, Poplack, DG, Costin, D & Minna, JD 1993, 'A novel germline P53 splicing mutation in a pediatric patient with a second malignant neoplasm', Oncogene, vol. 8, no. 5, pp. 1203-1210.
Felix CA, Strauss EA, D'Amico D, Tsokos M, Winter S, Mitsudomi T et al. A novel germline P53 splicing mutation in a pediatric patient with a second malignant neoplasm. Oncogene. 1993 May;8(5):1203-1210.
Felix, Carolyn A. ; Strauss, Eric A. ; D'Amico, Domenico ; Tsokos, Maria ; Winter, Stefan ; Mitsudomi, Tetsuya ; Nau, Marion M. ; Brown, Deborah L. ; Leahy, Ann M. ; Horowitz, Marc E. ; Poplack, David G. ; Costin, Dan ; Minna, John D. / A novel germline P53 splicing mutation in a pediatric patient with a second malignant neoplasm. In: Oncogene. 1993 ; Vol. 8, No. 5. pp. 1203-1210.
@article{671acf3423e848d1993105b4b5969afc,
title = "A novel germline P53 splicing mutation in a pediatric patient with a second malignant neoplasm",
abstract = "A novel germline p53 splicing mutation was identified in a pediatric patient with two metachronous primary cancers that are constituent tumors of the Li-Fraumeni syndrome. Genomic DNA from the second tumor showed the same mutation and loss of heterozygosity at the p53 locus. The mutant mRNA and protein were present in the tumor tissue. In contrast, in the normal tissues bearing the germline mutation in the heterozygous state, predominantly normal mRNA was expressed and the mutant p53 protein was not detectable. The functional silence and relative lack of mutant p53 mRNA expression in the normal tissues of this patient may be caused by decreased stability or decreased production. If this proves a more general pattern of expression of mutant p53 in individuals with germline mutations, these findings may explain the paucity of tumors in individuals affected with the Li-Fraumeni syndrome.",
author = "Felix, {Carolyn A.} and Strauss, {Eric A.} and Domenico D'Amico and Maria Tsokos and Stefan Winter and Tetsuya Mitsudomi and Nau, {Marion M.} and Brown, {Deborah L.} and Leahy, {Ann M.} and Horowitz, {Marc E.} and Poplack, {David G.} and Dan Costin and Minna, {John D.}",
year = "1993",
month = "5",
language = "English (US)",
volume = "8",
pages = "1203--1210",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - A novel germline P53 splicing mutation in a pediatric patient with a second malignant neoplasm

AU - Felix, Carolyn A.

AU - Strauss, Eric A.

AU - D'Amico, Domenico

AU - Tsokos, Maria

AU - Winter, Stefan

AU - Mitsudomi, Tetsuya

AU - Nau, Marion M.

AU - Brown, Deborah L.

AU - Leahy, Ann M.

AU - Horowitz, Marc E.

AU - Poplack, David G.

AU - Costin, Dan

AU - Minna, John D.

PY - 1993/5

Y1 - 1993/5

N2 - A novel germline p53 splicing mutation was identified in a pediatric patient with two metachronous primary cancers that are constituent tumors of the Li-Fraumeni syndrome. Genomic DNA from the second tumor showed the same mutation and loss of heterozygosity at the p53 locus. The mutant mRNA and protein were present in the tumor tissue. In contrast, in the normal tissues bearing the germline mutation in the heterozygous state, predominantly normal mRNA was expressed and the mutant p53 protein was not detectable. The functional silence and relative lack of mutant p53 mRNA expression in the normal tissues of this patient may be caused by decreased stability or decreased production. If this proves a more general pattern of expression of mutant p53 in individuals with germline mutations, these findings may explain the paucity of tumors in individuals affected with the Li-Fraumeni syndrome.

AB - A novel germline p53 splicing mutation was identified in a pediatric patient with two metachronous primary cancers that are constituent tumors of the Li-Fraumeni syndrome. Genomic DNA from the second tumor showed the same mutation and loss of heterozygosity at the p53 locus. The mutant mRNA and protein were present in the tumor tissue. In contrast, in the normal tissues bearing the germline mutation in the heterozygous state, predominantly normal mRNA was expressed and the mutant p53 protein was not detectable. The functional silence and relative lack of mutant p53 mRNA expression in the normal tissues of this patient may be caused by decreased stability or decreased production. If this proves a more general pattern of expression of mutant p53 in individuals with germline mutations, these findings may explain the paucity of tumors in individuals affected with the Li-Fraumeni syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0027191248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027191248&partnerID=8YFLogxK

M3 - Article

C2 - 8479743

AN - SCOPUS:0027191248

VL - 8

SP - 1203

EP - 1210

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 5

ER -